Oncology

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

By

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

By

Roche also announced first-quarter sales shrank 1%.

UK court OKs Herceptin biosimilar

A London court knocked down two Roche/Genentech patents, making a clearer path for biosimilars of the breast cancer drug. The primary patent lapses in July.

Halozyme pancreatic drug study on FDA hold

Halozyme pancreatic drug study on FDA hold

By

The FDA issued an official halt, five days after Halozyme stopped the Phase-II trial because of patient stroke information.

Lilly's CDK 4/6 inhibitor a cancer contender

Lilly's CDK 4/6 inhibitor a cancer contender

By

Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.

Pfizer palbociclib news divides investors

Pfizer palbociclib news divides investors

By

Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.

Lilly Alimta patent extended to 2022

Lilly Alimta patent extended to 2022

By

A court granted Lilly six more years of patent protection for the almost $3-billion-dollar-a-year cancer drug.

GSK pulls EMA Tafinlar/Mekinist application

GSK pulls EMA Tafinlar/Mekinist application

By

The company said it wants to wait for more data to come in.

ASCO will grade drugs

The professional association says it's necessary, because high prices do not indicate impact.

NICE says no to Xofigo, Zaltrap

NICE says no to Xofigo, Zaltrap

By

The UK's National Institute for Health and Care Excellence says it bounced Bayer's drug for failing to compare itself to current treatments, and Sanofi's over cost.

GSK drug fails in lung patients

The company says it will continue to test its MAGE-A3 cancer drug among a subset of non-small cell lung cancer patients and among melanoma patients.

Astellas seeks new Xtandi indication

Astellas and Medivation have applied for a pre-chemo indication for the cancer drug.

ASCO defines meaningful

A working group set out parameters for what counts as a meaningful outcome for pancreatic, breast, lung and colon cancer clinical trials.

Nexavar fails recurrence target

Nexavar fails recurrence target

By

Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.

BMS jumps to Ph.III lung cancer study

BMS jumps to Ph.III lung cancer study

By

The drugmaker announced Tuesday that it will pursue a Phase-III Yervoy-nivolumab study.

At-home colon kit increases screening rates

A pilot program including mailed colon-cancer screening tests increased use of the tests among under-served patients.

Avastin helps cervical cancer patients

Adding Avastin to chemotherapy added four months of survival, data show.

Merck sends HPV vax to FDA

Merck sends HPV vax to FDA

By

The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.

Lilly's ramu' has squamous, non-squamous potential

Lilly's ramu' has squamous, non-squamous potential

By

The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.

Novartis expands immuno-oncology presence

Novartis expands immuno-oncology presence

By

The drugmaker's purchase of private biotech CoStim Pharmaceuticals comes with a host of experimental immuno-oncology agents.

J&J cancer med adds indication, lower dose

J&J cancer med adds indication, lower dose

By

The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.

Panel urges increased HPV vaccination rates

Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.

Roche silences Herceptin comparison

A court in India ruled biosimilar drug makers will not be able to cite the drug's name, efficacy or safety profile in its marketing.

Merck: 2014 is the year of the rebuild

Merck: 2014 is the year of the rebuild

By

The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.

Report: cancer rates will continue to rise

Report: cancer rates will continue to rise

By

The proposed solutions include education, access and low-cost interventions.

Pfizer releases Ph. II palbociclib data

Pfizer releases Ph. II palbociclib data

By

The company said in a statement that it is talking with the FDA about next steps. Data on overall survival—a key metric for how oncologists view new cancer meds—remains under wraps.

Merck, Ablynx ink immunotherapy deal

The two will explore cancer-attacking nanobodies.

NIH finds new bladder cancer targets

New research finds overlap with some forms of breast, lung, and head & neck cancers, as well as 32 recurring genetic mutations.

BMS backs Stand Up To Cancer lung research

The drug maker is kicking in $5 million—or 20% of funding—for the research "dream team," which is part of an alliance between Stand Up and the American Cancer Society.

Medivation's Xtandi could eat into Zytiga turf

Medivation's Xtandi could eat into Zytiga turf

By

A clinical trial shows that using Xtandi before chemotherapy—Zytiga's indication—improves progression-free survival.

Email Newsletters